DAPAGLIFLOZIN 10mg. IP + SITAGLIPTIN PHOSPHATE 100mg. IP

A potent dual approach to help patients maintain healthier blood sugar levels. Controls blood sugar levels in patients when diet and exercise alone are not sufficient. Improves glycemic control by reducing glucose reabsorption (Dapagliflozin) and enhancing insulin release & suppressing glucagon secretion. (Sitagliptin). (Rana Bhattacharjee, 2023) Dapagliflozin reduces glucose reabsorption in the kidneys, allowing glucose to be excreted in the urine. (Manoj Chawla, 2024) Sitagliptin increases insulin release and decreases the amount of glucose produced by the liver by inhibiting the dipeptidyl peptidase 4 enzyme. (Manoj Chawla, 2024) A well-tolerated agent for type 2 diabetes patients inadequately controlled on sitagliptin, with or without metformin. (Serge A Jabbour & Group, 2014) A promising and well-tolerated option for managing T2DM, addressing both glycemic control and cardiovascular health. (Manoj Chawla, 2024) Provides synergistic benefits for type 2 diabetes patients, improving glycemic control, reducing weight, and maintaining good tolerability without increasing hypoglycemia risk. (Manoj Chawla, 2024) An effective and safe antidiabetic drug in reducing blood glucose levels and body mass index in the Indian population with T2DM. (Rana Bhattacharjee, 2023) A promising treatment option for patients with type 2 diabetes (T2DM). (Rana Bhattacharjee, 2023) Significantly improves glycemic control and lipid profiles in T2DM patients, especially those with coronary artery disease. (Manoj Chawla, 2024) An alternative treatment option for patients with type 2 diabetes who have not achieved sufficient glycemic control with monotherapy or dual therapy. (Rana Bhattacharjee, 2023) Targets glycemic control and also offers cardiovascular, renal, weight, and blood pressure benefits. (Rana Bhattacharjee, 2023) An effective and well-tolerated option for T2DM patients with established cardiovascular disease. (Manoj Chawla, 2024) Significantly decreases HbA1c levels from 8.9 to 7.2, fasting blood glucose fell from 178.8 to 124.0 and postprandial glucose dropped from 273.9 to 176.0 after 12 weeks of treatment. (Manoj Chawla, 2024)